The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review

Dhanashree Wankhade; Pankaj Gharde; Sushmita Dutta

doi:10.7759/cureus.49742

journal article Nov 30, 2023

The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review

Dhanashree Wankhade Pankaj Gharde Sushmita Dutta

Cureus · Springer Science and Business Media LLC

View at Publisher Save 10.7759/cureus.49742

Topics

No keywords indexed for this article. Browse by subject →

References

52

[1]

Zhou X, Li Y. Local recurrence after breast-conserving surgery and mastectomy following neoadjuvant chemotherapy for locally advanced breast cancer - a meta-analysis. Breast Care (Basel). 2016, 11:345-51. 10.1159/000450626 10.1159/000450626

[2]

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr. 2001, 96-102. 10.1093/oxfordjournals.jncimonographs.a003469 10.1093/oxfordjournals.jncimonographs.a003469

[3]

Chen AM, Meric-Bernstam F, Hunt KK, et al.. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004, 22:2303-12. 10.1200/JCO.2004.09.062 10.1200/jco.2004.09.062

[4]

Hurley J, Reis IM, Rodgers SE, et al.. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat. 2013, 138:783-94. 10.1007/s10549-013-2497-y 10.1007/s10549-013-2497-y

[5]

Romero A, García-Sáenz JA, Fuentes-Ferrer M, et al.. Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Ann Oncol. 2013, 24:655-61. 10.1093/annonc/mds493 10.1093/annonc/mds493

[6]

Nolen BM, Marks JR, Ta'san S, et al.. Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res. 2008, 10:R45. 10.1186/bcr2096 10.1186/bcr2096

[7]

Luangdilok S, Samarnthai N, Korphaisarn K. Association between pathological complete response and outcome following neoadjuvant chemotherapy in locally advanced breast cancer patients. J Breast Cancer. 2014, 17:376-85. 10.4048/jbc.2014.17.4.376 10.4048/jbc.2014.17.4.376

[8]

Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006, 11:574-89. 10.1634/theoncologist.11-6-574 10.1634/theoncologist.11-6-574

[9]

Tufano AM, Teplinsky E, Landry CA. Updates in neoadjuvant therapy for triple negative breast cancer. Clin Breast Cancer. 2021, 21:1-9. 10.1016/j.clbc.2020.07.001 10.1016/j.clbc.2020.07.001

[10]

An J, Peng C, Tang H, Liu X, Peng F. New advances in the research of resistance to neoadjuvant chemotherapy in breast cancer. Int J Mol Sci. 2021, 22:9644. 10.3390/ijms22179644 10.3390/ijms22179644

[11]

Shen G, Zhao F, Huo X, Ren D, Du F, Zheng F, Zhao J. Meta-analysis of HER2-enriched subtype predicting the pathological complete response within HER2-positive breast cancer in patients who received neoadjuvant treatment. Front Oncol. 2021, 11:632357. 10.3389/fonc.2021.632357 10.3389/fonc.2021.632357

[12]

Iwamoto T, Kajiwara Y, Zhu Y, Iha S. Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. Chin Clin Oncol. 2020, 9:27. 10.21037/cco.2020.01.06 10.21037/cco.2020.01.06

[13]

Provenzano E. Neoadjuvant chemotherapy for breast cancer: moving beyond pathological complete response in the molecular age. Acta Med Acad. 2021, 50:88-109. 10.5644/ama2006-124.328 10.5644/ama2006-124.328

[14]

Tse T, Sehdev S, Seely J, Gravel DH, Clemons M, Cordeiro E, Arnaout A. Neoadjuvant chemotherapy in breast cancer: review of the evidence and conditions that facilitated its use during the global pandemic. Curr Oncol. 2021, 28:1338-47. 10.3390/curroncol28020127 10.3390/curroncol28020127

[15]

Korde LA, Somerfield MR, Carey LA, et al.. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol. 2021, 39:1485-505. 10.1200/JCO.20.03399 10.1200/jco.20.03399

[16]

Shien T, Iwata H. Adjuvant and neoadjuvant therapy for breast cancer. Jpn J Clin Oncol. 2020, 50:225-9. 10.1093/jjco/hyz213 10.1093/jjco/hyz213

[17]

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis Slamon, Wolfgang Eiermann, Nicholas Robert et al.

New England Journal of Medicine 2011 10.1056/nejmoa0910383

[18]

Buzdar AU, Ibrahim NK, Francis D, et al.. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005, 23:3676-85. 10.1200/JCO.2005.07.032 10.1200/jco.2005.07.032

[19]

Asselain B, Barlow W, Bartlett J, et al.. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018, 19:27-39. 10.1016/S1470-2045(17)30777-5 10.1016/s1470-2045(17)30777-5

[20]

von Minckwitz G, Untch M, Blohmer JU, et al.. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012, 30:1796-804. 10.1200/JCO.2011.38.8595 10.1200/jco.2011.38.8595

[21]

Gianni L, Pienkowski T, Im Y-H, et al.. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (neoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012, 13:25-32. 10.1016/S1470-2045(11)70336-9 10.1016/s1470-2045(11)70336-9

[22]

Zhao Y, Schaafsma E, Cheng C. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy. Cancer Med. 2020, 9:6281-95. 10.1002/cam4.3284 10.1002/cam4.3284

[23]

Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast. 2022, 62 Suppl 1:S12-16. 10.1016/j.breast.2022.01.006 10.1016/j.breast.2022.01.006

[24]

Fisher CS. Neoadjuvant chemotherapy for breast cancer: the ultimate “spy”. Ann Surg Oncol. 2022, 29:6508-10. 10.1245/s10434-022-12153-4 10.1245/s10434-022-12153-4

[25]

Pesapane F, Agazzi GM, Rotili A, et al.. Prediction of the pathological response to neoadjuvant chemotherapy in breast cancer patients with MRI-radiomics: a systematic review and meta-analysis. Curr Probl Cancer. 2022, 46:100883. 10.1016/j.currproblcancer.2022.100883 10.1016/j.currproblcancer.2022.100883

[26]

See SH, Siziopikou KP. Pathologic evaluation of specimens after neoadjuvant chemotherapy in breast cancer: current recommendations and challenges. Pathol Res Pract. 2022, 230:153753. 10.1016/j.prp.2021.153753 10.1016/j.prp.2021.153753

[27]

Oikawa M. The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer. Chin Clin Oncol. 2020, 9:29. 10.21037/cco-20-12 10.21037/cco-20-12

[28]

Leon-Ferre RA, Hieken TJ, Boughey JC. The landmark series: neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer. Ann Surg Oncol. 2021, 28:2111-19. 10.1245/s10434-020-09480-9 10.1245/s10434-020-09480-9

[29]

Schmid P, Cortes J, Dent R, et al.. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022, 386:556-67. 10.1056/NEJMoa2112651 10.1056/nejmoa2112651

[30]

Pembrolizumab and atezolizumab in triple-negative breast cancer

Dorota Kwapisz

Cancer Immunology, Immunotherapy 2021 10.1007/s00262-020-02736-z

[31]

Radovich M, Jiang G, Hancock BA, et al.. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the Bre12-158 randomized clinical trial. JAMA Oncol. 2020, 6:1410-15. 10.1001/jamaoncol.2020.2295 10.1001/jamaoncol.2020.2295

[32]

Yuan Y, Lee JS, Yost SE, et al.. Phase II trial of neoadjuvant carboplatin and nab-paclitaxel in patients with triple-negative breast cancer. Oncologist. 2021, 26:e382-93. 10.1002/onco.13574 10.1002/onco.13574

[33]

Torrisi R, Marrazzo E, Agostinetto E, et al.. Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: when, why and what?. Crit Rev Oncol Hematol. 2021, 160:103280. 10.1016/j.critrevonc.2021.103280 10.1016/j.critrevonc.2021.103280

[34]

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar, Lijun Zhang, Michael Untch et al.

The Lancet 2014 10.1016/s0140-6736(13)62422-8

[35]

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess et al.

Journal of Clinical Oncology 2008 10.1200/jco.2007.14.4147

[36]

Earl HM, Hiller L, Dunn JA, et al.. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015, 16:656-66. 10.1016/S1470-2045(15)70137-3 10.1016/s1470-2045(15)70137-3

[37]

Li Y, Yang D, Chen P, Yin X, Sun J, Li H, Ren G. Efficacy and safety of neoadjuvant chemotherapy regimens for triple-negative breast cancer: a network meta-analysis. Aging (Albany NY). 2019, 11:6286-311. 10.18632/aging.102188 10.18632/aging.102188

[38]

Joensuu H, Gligorov J. Adjuvant treatments for triple-negative breast cancers. Ann Oncol. 2012, 23 Suppl 6:vi40-5. 10.1093/annonc/mds194 10.1093/annonc/mds194

[39]

Biswas T, Efird JT, Prasad S, Jindal C, Walker PR. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget. 2017, 8:112712-9. 10.18632/oncotarget.22521 10.18632/oncotarget.22521

[40]

Rastogi P, Anderson SJ, Bear HD, et al.. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008, 26:778-85. 10.1200/JCO.2007.15.0235 10.1200/jco.2007.15.0235

[41]

Rodler ET, Kurland BF, Griffin M, et al.. Phase I study of veliparib (ABT-888) combined with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer. Clin Cancer Res. 2016, 22:2855-64. 10.1158/1078-0432.CCR-15-2137 10.1158/1078-0432.ccr-15-2137

[42]

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

C.E. Geyer, W.M. Sikov, J. Huober et al.

Annals of Oncology 2022 10.1016/j.annonc.2022.01.009

[43]

Sharma P, Kimler BF, O'Dea A, et al.. Randomized Phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clin Cancer Res. 2021, 27:975-82. 10.1158/1078-0432.CCR-20-3646 10.1158/1078-0432.ccr-20-3646

[44]

Wu J, Jiang Z, Liu Z, et al.. Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 2022, 20:498. 10.1186/s12916-022-02708-3 10.1186/s12916-022-02708-3

[45]

LeVasseur N, Sun J, Gondara L, Diocee R, Speers C, Lohrisch C, Chia S. Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis. J Cancer Res Clin Oncol. 2020, 146:529-36. 10.1007/s00432-019-03083-y 10.1007/s00432-019-03083-y

[46]

Minckwitz G von, Schneeweiss A, Loibl S, et al.. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (geparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014, 15:747-56. 10.1016/S1470-2045(14)70160-3 10.1016/s1470-2045(14)70160-3

[47]

Sharma P, Connolly RM, Roussos Torres ET, Thompson A. Best foot forward: neoadjuvant systemic therapy as standard of care in triple-negative and HER2-positive breast cancer. Am Soc Clin Oncol Educ Book. 2020, 40:1-16. 10.1200/EDBK_281381 10.1200/edbk_281381

[48]

Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020, 9:32. 10.21037/cco-20-123 10.21037/cco-20-123

[49]

Yin W, Wang Y, Wu Z, et al.. Neoadjuvant trastuzumab and pyrotinib for locally advanced HER2-positive breast cancer (NeoATP): primary analysis of a phase II study. Clin Cancer Res. 2022, 28:3677-85. 10.1158/1078-0432 10.1158/1078-0432

[50]

Zhang L, Wang Y, Zhang L, Xing H, Niu C, Yu Q, Tang L. Invasive micropapillary carcinoma with CEP17 monosomy of the bilateral breast: a rare case report and review of the literature. Onco Targets Ther. 2020, 13:6425-32. 10.2147/OTT.S251934 10.2147/ott.s251934

Showing 50 of 52 references

Metrics

1

Citations

52

References

Details

Published: Nov 30, 2023

Authors

Cite This Article

Dhanashree Wankhade, Pankaj Gharde, Sushmita Dutta (2023). The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review. Cureus. https://doi.org/10.7759/cureus.49742

The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review

You May Also Like